In vivo Grade Recombinant MOPC-21 Mouse IgG1 Isotype Control Antibody

Artikelnummer: ABB-YR0238
Artikelname: In vivo Grade Recombinant MOPC-21 Mouse IgG1 Isotype Control Antibody
Artikelnummer: ABB-YR0238
Hersteller Artikelnummer: YR0238
Alternativnummer: ABB-YR0238-5MG
Hersteller: ABclonal
Kategorie: Antikörper
Applikation: FC, IHC-Fr, IHC-P, IP, WB
The MOPC-21 antibody (IgG1, kappa) has been used for a long time as an isotype-matched control antibody to estimate the degree of non-specific binding by an antigen-specific antibody. The variable regions of the MOPC-21 antibody share the sequences with the antibodies against all members of the dengue virus complex, and the Epstein-Barr virus gp350 protein. The recombinant MOPC-21 IgG1 kappa isotype control and mutants (natural and engineered mIgG1 isotype controls) are useful for in vitro and in vivo studies from ELISA, Western blot (WB), to cell-based assay to animal model study. Mouse IgG1 isotype control and mutants (natural and engineered mIgG1 isotype controls) are useful for in vitro and in vivo studies from ELISA, Western blot (WB), to cell-based assay to animal model study. The isotypes of mouse IgG antibody reagents used in scientific research and clinical diagnostics are mainly mouse IgG1 kappa. Mouse IgG1 antibodies and engineered mutants are also used in therapeutic drug discovery. Mouse IgG1 antibodies are more like human IgG4 antibodies than human IgG1 antibodies, which behave more like mouse IgG2a or IgG2c antibodies. Many antibody drugs especially those targetting immune checkpoint proteins use the human IgG4 constant regions.As an ideal recombinant mouse IgG1 isotype control, the recombinant MOPC-21 mIgG1 kappa isotype control has low or no specific binding to any mouse sample, and completely mouse variable regions and the mouse IgG1 kappa constant regions. The mouse IgG1 kappa isotype control and mutants can be used in ELISA, Western blot (WB), the cell-based assay or animal model as the antibody negative control.
Reinheit: >95% Determined by SDS-PAGE
Anwendungsbeschreibung: Cross-Reactivity: <1EU/mg (<0.001EU/µg)Determined by LAL gel clotting assay